KeyBanc lowered the firm's price target on ICU Medical to $164 from $180 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The firm believes underlying MedTech trends continue to track well ahead of subdued market performance, which it thinks is mostly attributable to various macro items weighing on investor sentiment.
